Gilead Sciences | GILD - Ebitda

Aktienkurs
142.09
Täglich Wechseln
0.55 0.39%
Monatlich
-4.36%
Jährlich
40.13%
Q2 Prognose
135.50




Ebitda Veränderung Datum
AbbVie USD 3.52B 828M 2025-09
Agios Pharmaceuticals USD -115.49M 10.3M 2025-09
ALKERMES USD 100.31M 21.24M 2025-12
Alnylam Pharmaceuticals USD 145.22M 236.56M 2025-12
Amgen USD 5.14B 775M 2025-12
Biogen USD 573.2M 253.7M 2025-12
BioMarin Pharmaceutical USD -24.17M 18.91M 2025-12
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Coherus Biosciences USD -43.33M 4.7M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Gilead Sciences USD 4.03B 628M 2025-09
GlaxoSmithKline GBP 3.36B 179M 2025-09
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Incyte USD 414.5M 92.42M 2025-12
J&J USD 9.52B 389M 2025-09
Merck USD 8.39B 1.97B 2025-09
Moderna USD -790M 582M 2025-12
Neurocrine Biosciences USD 218.4M 28.3M 2025-12
Novartis USD 4.77B 1.11B 2025-12
Pfizer USD 6.08B 351M 2025-09
PTC Therapeutics USD 20.63M 53.74M 2025-09
Puma Biotechnology USD 729K 11.36M 2024-06
Regeneron Pharmaceuticals USD 1.92B 261.9M 2025-09
Sanofi EUR 4.84B 2.95B 2025-09
Sarepta Therapeutics USD -168.03M 294.45M 2025-09
United Therapeutics USD 379.5M 83.4M 2025-12
Vertex Pharmaceuticals USD 1.44B 100.4M 2025-09